PASG net incomeQ2 2026-$7.82M
PASG net income was -$7.82M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$9.38M a year earlier. For the full fiscal 2025 it was -$45.52M, compared with -$64.77M in fiscal 2024.
Passage Bio Inc. (PASG) financials
For the twelve months ended Jun 30, 2026, Passage Bio Inc. reported -$36.11M of net income.
- Net income, TTM
- -$36.11M
- EPS, diluted, TTM
- -$11.32
- Cash
- $24.16M
- Market cap
- $12.8M
FY2019FY2025
PASG revenue and earnings growth
PASG EPSQ2 2026-$2.44
PASG diluted EPS was -$2.44 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.96 a year earlier. For the full fiscal 2025 it was -$14.35, compared with -$21.04 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Research and development | $23.28M | $40.18M | $61.42M | $86.05M | $117.67M | $81.79M | $29.74M |
| Selling, general and admin | $19.88M | $24.99M | $41.58M | $49.34M | $60.06M | $30.11M | $6.95M |
| Operating income | -$49.30M | -$70.40M | -$108.39M | -$138.39M | -$185.73M | -$112.90M | -$37.19M |
| Income tax | $0 | $0 | - | - | - | - | - |
| Net income | -$45.52M | -$64.77M | -$102.06M | -$136.13M | -$185.39M | -$112.23M | -$45.63M |
| EPS, basic | -$14.35 | -$21.04 | -$36.58 | -$49.17 | -$68.44 | -$57.23 | -$211.81 |
| EPS, diluted | -$14.35 | -$21.04 | -$36.58 | -$49.17 | -$68.44 | -$57.23 | -$211.81 |
| Diluted shares | 3.2M | 3.1M | 2.8M | 2.8M | 2.7M | 2.0M | 215,392.932 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $46.30M | $37.57M | $21.71M | $34.60M | $128.97M | $135.00M | $158.87M |
| Current assets | $47.76M | $78.81M | $117.96M | $197.04M | $325.07M | $317.18M | $165.78M |
| Total assets | $62.28M | $102.41M | $150.54M | $243.55M | $355.08M | $328.01M | $178.61M |
| Current liabilities | $23.08M | $19.36M | $16.34M | $18.35M | $29.50M | $21.18M | $3.68M |
| Total liabilities | $43.53M | $41.15M | $39.26M | $42.18M | $36.42M | $23.29M | $4.26M |
| Shareholders' equity | $18.75M | $61.26M | $111.28M | $201.37M | $318.66M | $304.71M | -$56.25M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.51M | -$47.96M | -$78.26M | -$118.21M | -$126.88M | -$80.52M | -$39.90M |
| Capital expenditures | - | $34.0K | - | - | - | - | - |
| Free cash flow | - | -$47.99M | - | - | - | - | - |
| Investing cash flow | $40.22M | $54.95M | $65.24M | $25.20M | -$45.81M | -$172.11M | -$1.69M |
| Financing cash flow | $23.0K | $8.87M | $135.0K | -$1.35M | $166.66M | $228.75M | $175.60M |
| Stock-based compensation | $3.00M | $5.82M | $10.92M | $18.95M | $32.69M | $14.58M | $1.45M |
| Depreciation and amortization | $728.0K | $3.08M | $3.72M | $3.68M | $1.54M | $800.0K | $134.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Return on equity | -242.7% | -105.7% | -91.7% | -67.6% | -58.2% | -36.8% | - |
| Return on assets | -73.1% | -63.2% | -67.8% | -55.9% | -52.2% | -34.2% | -25.5% |
| Current ratio | 2.07 | 4.07 | 7.22 | 10.74 | 11.02 | 14.98 | 45.04 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.34M | $4.09M | $5.42M | $4.31M | $5.81M | $7.74M | $9.56M | $8.66M | $10.43M | $11.54M | $12.16M | $15.10M |
| Selling, general and admin | $6.87M | $4.79M | $4.92M | $4.35M | $4.52M | $6.08M | $4.71M | $7.25M | $6.51M | $6.51M | $6.29M | $8.18M |
| Operating income | -$8.27M | -$8.25M | -$13.85M | -$8.65M | -$10.33M | -$16.46M | -$14.27M | -$20.70M | -$17.38M | -$18.05M | -$18.45M | -$28.67M |
| Net income | -$7.82M | -$7.56M | -$12.98M | -$7.75M | -$9.38M | -$15.40M | -$12.72M | -$19.34M | -$15.99M | -$16.71M | -$16.76M | -$27.11M |
| EPS, basic | -$2.44 | -$2.36 | -$4.08 | -$2.44 | -$2.96 | -$4.87 | -$3.90 | -$6.15 | -$5.09 | -$5.90 | -$5.90 | -$9.64 |
| EPS, diluted | -$2.44 | -$2.36 | -$4.08 | -$2.44 | -$2.96 | -$4.87 | -$3.90 | -$6.15 | -$5.09 | -$5.90 | -$5.90 | -$9.64 |
| Diluted shares | 3.2M | 3.2M | - | 3.2M | 3.2M | 3.2M | - | 3.1M | 3.1M | 2.9M | - | 2.8M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $24.16M | $33.34M | $46.30M | $52.77M | $57.63M | $63.36M | $37.57M | $32.29M | $24.77M | $36.77M | $21.71M | $33.58M |
| Current assets | $25.18M | $34.74M | $47.76M | $55.73M | $60.31M | $66.67M | $78.81M | $87.22M | $95.00M | $108.29M | $117.96M | $135.71M |
| Total assets | $25.18M | $36.46M | $62.28M | $74.16M | $79.20M | $86.01M | $102.41M | $111.75M | $125.39M | $140.53M | $150.54M | $169.26M |
| Current liabilities | $20.72M | $20.10M | $23.08M | $22.25M | $19.80M | $17.82M | $19.36M | $16.95M | $12.38M | $12.84M | $16.34M | $19.81M |
| Total liabilities | $20.72M | $24.71M | $43.53M | $43.04M | $40.94M | $39.30M | $41.15M | $39.04M | $34.84M | $35.65M | $39.26M | $42.98M |
| Shareholders' equity | $4.46M | $11.75M | $18.75M | $31.12M | $38.26M | $46.71M | $61.26M | $72.72M | $90.56M | $104.88M | $111.28M | $126.28M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.18M | -$12.99M | -$6.48M | -$4.85M | -$6.33M | -$13.85M | -$8.44M | -$7.45M | -$13.14M | -$18.93M | -$19.52M | -$19.16M |
| Investing cash flow | $0 | $20.0K | $0 | $0 | $585.0K | $39.63M | $13.68M | $14.97M | $1.05M | $25.25M | $7.60M | $22.45M |
| Financing cash flow | - | - | $9.0K | $0 | - | - | $47.0K | $0 | $85.0K | $8.74M | $46.0K | $0 |
| Stock-based compensation | $525.0K | $556.0K | $609.0K | $611.0K | $923.0K | $858.0K | $1.25M | $1.40M | $1.58M | $1.59M | $1.57M | $2.82M |
| Depreciation and amortization | $25.0K | $129.0K | $177.0K | $200.0K | $200.0K | $201.0K | $719.0K | $800.0K | $800.0K | $806.0K | $807.0K | $1.00M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 1.22 | 1.73 | 2.07 | 2.51 | 3.05 | 3.74 | 4.07 | 5.15 | 7.67 | 8.43 | 7.22 | 6.85 |
Source: XBRL data Passage Bio Inc. files with the SEC, latest filing dated Aug 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 3-for-59, first reported Aug 12, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
PASG peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PASG | - | - | -$36.11M | - | $12.8M |
| TSHA | $5.49M | -32.3% | -$149.63M | -2728.0% | $1.41B |
| PALI | $500.0K | - | -$31.94M | -6388.2% | $196.9M |
| TIL | $8.97M | +2.5% | -$30.28M | -337.7% | $46.3M |
PASG FAQ
5 questionsIs PASG profitable?
No. Passage Bio Inc. reported a net loss of $36.11M for the twelve months ended Jun 30, 2026.How much cash and debt does PASG have?
Passage Bio Inc. reported $24.16M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is PASG earnings per share?
Diluted earnings per share were -$11.32 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did PASG last report financial results?
The latest statements here come from Passage Bio Inc.'s 10-Q filed on Aug 10, 2026, covering the period ended Jun 30, 2026.Where does this PASG financial data come from?
Quantisnow builds these statements from the structured XBRL data Passage Bio Inc. files with the SEC. It is provided for information only and is not investment advice.